Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-15
2009-11-17
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S208000
Reexamination Certificate
active
07618987
ABSTRACT:
Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
REFERENCES:
patent: 6294534 (2001-09-01), Nargund et al.
patent: 6350760 (2002-02-01), Bakshi et al.
patent: 6376509 (2002-04-01), Bakshi et al.
patent: 6410548 (2002-06-01), Nargund et al.
patent: 6458790 (2002-10-01), Palucki et al.
patent: 6472398 (2002-10-01), Palucki et al.
patent: 6713487 (2004-03-01), Yu et al.
patent: 6818658 (2004-11-01), Ujjainwalla et al.
patent: 7015235 (2006-03-01), Goulet et al.
patent: 2002/0004512 (2002-01-01), Bakshi et al.
patent: 2002/0019523 (2002-02-01), Palucki et al.
patent: 2002/0137664 (2002-09-01), Bakshi et al.
patent: 2003/0092732 (2003-05-01), Yu et al.
patent: 2004/0097546 (2004-05-01), Goulet et al.
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/58891 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/15909 (2002-02-01), None
patent: WO 02/067869 (2002-09-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 02/079146 (2002-10-01), None
patent: WO 03/007949 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/057671 (2003-07-01), None
patent: WO 03/066597 (2003-08-01), None
patent: WO 03/068738 (2003-08-01), None
patent: WO 03/092690 (2003-11-01), None
patent: WO 2004/024720 (2004-03-01), None
patent: WO 2004/037797 (2004-05-01), None
patent: WO 2004/078716 (2004-06-01), None
patent: WO 2004/078717 (2004-09-01), None
Fischer et. al. “Privileged structure based ligands for melanocortin receptors-Substituted benzylic piperazine derivatives” . Bioorganic & Medicinal Chemistry Letters 2005, 15, 4973-4978.
Hogan et. al. “Mapping the Binding Site of Melanocortin 4 Receptor Agonists: A Hydrophobic Pocket Formed by 13.28(125), 13.32(129), and 17.42(291) Is Critical for Receptor Activation” Journal of Medicinal Chemistry 2006, 49, 911-922.
Sebhat et. al. “Melanocortin subtype 4 receptor agonists: Structure-activity relationships about the 4-alkyl piperidine core” Bioorganic & Medicinal Chemistry Letters 2007, 17, 5720-5723.
Guo et. al. “Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators” Bioorganic & Medicinal Chemistry Letters 2008, 18, 3242-3247.
Poitout et. al. “Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor” Bioorganic & Medicinal Chemistry Letters 2007, 17, 4464-4470.
Bakshi Raman K.
Dellureficio James P.
Nargund Ravi P.
Brown Eaerbel R.
Desai Rita J
Fitch Catherine D.
Merck & Co. , Inc.
O'Dell David K
LandOfFree
Acylated piperidine derivatives as melanocortin 4-receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated piperidine derivatives as melanocortin 4-receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated piperidine derivatives as melanocortin 4-receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144544